Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nimacimab · JNJ-2463, RYI-018

Other · developed by Skye Bioscience

Phase 2 Most advanced trial
SKYE Developer
1 Registered trials

What is Nimacimab?

Nimacimab is an investigational agent studied in obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
JNJ-2463, RYI-018
Drug type
Other
Therapy area
Metabolic
Developer
Skye Bioscience, Inc. (SKYE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
85TS31SOL3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06577090 Phase 2 Obesity Active not recruiting SKYE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obesity

More from Skye Bioscience

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SKYE page.

Follow SKYE, the company behind Nimacimab

See SKYE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SKYE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.